Soleus Capital Management, L.P.
Position in SYRE — Spyre Therapeutics, Inc.
CIK 1802630
GREENWICH, CT
Position in SYRE
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$13,050,660
New position
Shares Held
147,000
first reported quarter
Ownership
0.167%
of shares outstanding
% of Portfolio
0.45%
of 13F equity value
Holder Rank
#64
of 266 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Soleus Capital Management, L.P. holds $1,753,981,438 across 64 Biotechnology names. SYRE ranks #32 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KRYS |
Krystal Biotech, Inc.
|
939,254 | $349,092,534 | |
| 2 | CELC |
Celcuity Inc.
|
1,704,318 | $178,305,749 | |
| 3 | TGTX |
Tg Therapeutics, Inc.
|
2,927,895 | $160,858,551 | |
| 4 | RIGL |
Rigel Pharmaceuticals Inc
|
1,843,504 | $72,117,876 | |
| 5 | VCEL |
Vericel Corp
|
1,459,152 | $64,917,672 | |
| 6 | PRAX |
Praxis Precision Medicines, Inc.
|
177,517 | $59,430,916 | |
| 7 | GERN |
Geron Corp
|
42,808,659 | $54,795,083 | |
| 8 | ERAS |
Erasca, Inc.
|
2,700,000 | $49,464,000 |
All Filings in SYRE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13,050,660 | 147,000 | Shares | Sole | 2026-08-11 | |
| No filing history on record for this holder in this stock. | ||||||